Researchers at the University of Pittsburgh Center for Vaccine Research (CVR) have developed an engineered antimicrobial peptide effective against co-infection by bacterial microfilm and a virus, and as such is a possible new therapeutic agent against chronic and antibiotic-resistant infections. Importantly, the potential drug was tested against Pseudomonas aeruginosa, one of the primary and more dangerous bacterial strains causing lung infections in cystic fibrosis patients.
New Antimicrobial Peptide May Be Able... - Lung Conditions C...
New Antimicrobial Peptide May Be Able to Treat Even Drug-Resistant CF Lung Infections.
Hello 2Greys, so good to see you back with your helpful links to research. Apologies if I missed an earlier post. I have been quite busy and I may have missed it.
All the best and take special care
Kate xx
Morning & Welcome Back 2 Gs, Saw your Name and went Hooray , He's back. Hope you & Sharon are feeling Better, Much love to you Both,... Now I'll read your Post. XXX C.
This would be good news for COPD and bronchiectasis sufferers too, surely?
Of course it will be, Pseudomonas aeruginosa is not an exclusive infection of CF patients, Bronchs will most certainly benefit. It is just that this is reported in Cystic Fibrosis News Today which is obviously biased towards CF. No doubt there maybe opportunities to re-purpose the drug in other Gram-negative bacterial infections as well.